Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine - PubMed (original) (raw)

. 2004 Jun 1;64(11):4001-9.

doi: 10.1158/0008-5472.CAN-03-2984.

Giordano Nicoletti, Lorena Landuzzi, Annalisa Astolfi, Stefania Croci, Alberto Comes, Silvano Ferrini, Raffaella Meazza, Manuela Iezzi, Emma Di Carlo, Piero Musiani, Federica Cavallo, Patrizia Nanni, Pier-Luigi Lollini

Affiliations

• PMID: 15173014
• DOI: 10.1158/0008-5472.CAN-03-2984

Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine

Carla De Giovanni et al. Cancer Res. 2004.

Abstract

This study evaluated the ability of cytokine-engineered allogeneic (H-2(q)) HER-2/neu-positive cells to prevent tumor development in mammary cancer-prone virgin female BALB/c (H-2(d)) mice transgenic for the transforming rat HER-2/neu oncogene (BALB-neuT mice). Repeated vaccinations with cells engineered to release interleukin (IL)-2, IL-12, IL-15, or IFN-gamma showed that IL-12-engineered cell vaccines had the most powerful immunopreventive activity, with >80% of 1-year-old BALB-neuT mice free of tumors. On the contrary all of the untreated mice and all of the mice vaccinated with IL-12-engineered cells lacking either HER-2/neu or allogeneic antigens developed mammary carcinomas within 22 or 33 weeks, respectively. Whole mount, histology, immunohistochemistry, and gene expression profile analysis showed that vaccination with IL-12-engineered cells maintained 26-week mammary glands free of neoplastic growth, with a gene expression profile that clustered with that of untreated preneoplastic glands. The IL-12-engineered cell vaccine elicited a high production of IFN-gamma and IL-4 and a strong anti-HER-2/neu antibody response. Immune protection was lost or markedly impaired in BALB-neuT mice lacking IFN-gamma or antibody production, respectively. The protection afforded by the IL-12-engineered cell vaccine was equal to that provided by the systemic administration of recombinant IL-12 in combination with HER-2/neu H-2(q) cell vaccine. However, IL-12-engineered cell vaccine induced much lower circulating IL-12 and IFN-gamma, and therefore lower potential side effects and systemic toxicity.

PubMed Disclaimer

Similar articles

• Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
  Pupa SM, Iezzi M, Di Carlo E, Invernizzi A, Cavallo F, Meazza R, Comes A, Ferrini S, Musiani P, Ménard S. Pupa SM, et al. Cancer Res. 2005 Feb 1;65(3):1071-8. Cancer Res. 2005. PMID: 15705909
• Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
  Gritzapis AD, Voutsas IF, Lekka E, Papamichail M, Baxevanis CN. Gritzapis AD, et al. Cancer Res. 2010 Apr 1;70(7):2686-96. doi: 10.1158/0008-5472.CAN-09-2517. Epub 2010 Mar 16. Cancer Res. 2010. PMID: 20233867
• Antimetastatic activity of a preventive cancer vaccine.
  Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Antognoli A, Landuzzi L, Fabbi M, Ferrini S, Musiani P, Iezzi M, De Giovanni C, Lollini PL. Nanni P, et al. Cancer Res. 2007 Nov 15;67(22):11037-44. doi: 10.1158/0008-5472.CAN-07-2499. Cancer Res. 2007. PMID: 18006850
• Prevention by delay: nonspecific immunity elicited by IL-12 hinders Her-2/neu mammary carcinogenesis in transgenic mice.
  Gavallo F, Di Carlo E, Quaglin E, Jezzi M, Strasly M, Bussolino F, Colombo MP, Nanni P, Lollini PL, Musiani P, Forni G. Gavallo F, et al. J Biol Regul Homeost Agents. 2001 Oct-Dec;15(4):351-8. J Biol Regul Homeost Agents. 2001. PMID: 11860223 Review.
• [Novel vaccines against M. tuberculosis].
  Okada M. Okada M. Kekkaku. 2006 Dec;81(12):745-51. Kekkaku. 2006. PMID: 17240920 Review. Japanese.

Cited by

• Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment.
  Mehdizadeh R, Shariatpanahi SP, Goliaei B, Rüegg C. Mehdizadeh R, et al. Sci Rep. 2023 Apr 11;13(1):5875. doi: 10.1038/s41598-023-32554-z. Sci Rep. 2023. PMID: 37041172 Free PMC article.
• Dormant Tumor Cell Vaccination: A Mathematical Model of Immunological Dormancy in Triple-Negative Breast Cancer.
  Mehdizadeh R, Shariatpanahi SP, Goliaei B, Peyvandi S, Rüegg C. Mehdizadeh R, et al. Cancers (Basel). 2021 Jan 11;13(2):245. doi: 10.3390/cancers13020245. Cancers (Basel). 2021. PMID: 33440806 Free PMC article.
• Cancer Vaccines Co-Targeting HER2/Neu and IGF1R.
  De Giovanni C, Landuzzi L, Palladini A, Ianzano ML, Nicoletti G, Ruzzi F, Amici A, Croci S, Nanni P, Lollini PL. De Giovanni C, et al. Cancers (Basel). 2019 Apr 11;11(4):517. doi: 10.3390/cancers11040517. Cancers (Basel). 2019. PMID: 30979001 Free PMC article.
• OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis.
  Nanni P, De Giovanni C, Burocchi A, Nicoletti G, Landuzzi L, Palladini A, Ianzano ML, Arioli I, Colombo MP, Lollini PL. Nanni P, et al. Oncoimmunology. 2018 Jun 11;7(8):e1465164. doi: 10.1080/2162402X.2018.1465164. eCollection 2018. Oncoimmunology. 2018. PMID: 30221061 Free PMC article.
• Addressing current challenges in cancer immunotherapy with mathematical and computational modelling.
  Konstorum A, Vella AT, Adler AJ, Laubenbacher RC. Konstorum A, et al. J R Soc Interface. 2017 Jun;14(131):20170150. doi: 10.1098/rsif.2017.0150. J R Soc Interface. 2017. PMID: 28659410 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • Mouse Genome Informatics (MGI)

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal